Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
Strauss G, Lynch T, Elias A, Jacobs C, Herbst R, Leong T, Lynch C, Kwiatkowski D, Carey R, Grossbard M, Skarin A. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis. Seminars In Oncology 1997, 24: s12-73-s12-80. PMID: 9331127.Peer-Reviewed Original ResearchConceptsAdvanced lung cancerIfosfamide/carboplatin/etoposide chemotherapyCarboplatin/etoposide chemotherapySmall cell carcinomaCell carcinomaLung cancerResponse rateStage IIIAEtoposide chemotherapyMedian survivalGranulocyte colony-stimulating factor supportNon-small cell lung cancerColony-stimulating factor supportPreliminary survival analysisSingle-agent paclitaxelGrade 4 neutropeniaGrade 4 thrombocytopeniaLarge cell carcinomaCell lung cancerSquamous cell carcinomaGranulocyte colony-stimulating factorColony-stimulating factorNonhematologic toxicityPredominant toxicityHematologic toxicity